IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Pathology

• Publication date

  2011-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/path.2913PMID 21598255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased levels of hypoxia‐inducible factor‐1α are associated with Bcl‐xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma

  2011cited by this paper
• Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity

  2011cited by this paper
• Genome-wide analysis of Ollier disease: Is it all in the genes?

  2011cited by this paper
• Tiling resolution array‐CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients

  2011cited by this paper
• Cartilage tumours and bone development: molecular pathology and possible therapeutic targets

  2010cited by this paper
• Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors

  2010cited by this paper
• Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• IDH2 Mutations in Patients with d-2-Hydroxyglutaric Aciduria

  2010cited by this paper
• Cancer-associated IDH mutations: biomarker and therapeutic opportunities

  2010cited by this paper
• IDH mutations in glioma and acute myeloid leukemia.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010cited by this paper
• Whole-Genome Sequencing of a Single Proband Together with Linkage Analysis Identifies a Mendelian Disease Gene

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

  2010cited by this paper
• Tartrate resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature

  2010cited by this paper
• Enchondromatosis: insights on the different subtypes.

  2010cited by this paper
• Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

  2010cited by this paper
• Somatic gene mutation and human disease other than cancer: an update.

  2010cited by this paper
• Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway

  2009cited by this paper
• IDH 1 and IDH 2 Mutations in Gliomas

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• DO INTRACRANIAL NEOPLASMS DIFFER IN OLLIER DISEASE AND MAFFUCCI SYNDROME? AN IN‐DEPTH ANALYSIS OF THE LITERATURE

  2009cited by this paper
• Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Acute myelogenous leukemia associated with Ollier disease

  2008cited by this paper
• Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease

  2008cited by this paper
• PTHR1 mutations associated with Ollier disease result in receptor loss of function.

  2008cited by this paper
• Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas

  2006cited by this paper
• cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade

  2005cited by this paper
• Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression

  2004cited by this paper
• Case report 602

  2004cited by this paper
• Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study.

  2004cited by this paper
• Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C

  2004cited by this paper
• Multiple enchondromatosis Ollier's disease with two primary brain tumors.

  2004cited by this paper
• Spondyloenchondromatosis with D-2-hydroxyglutaric aciduria: a report of a second patient with this unusual combination

  2003cited by this paper
• A mutant PTH/PTHrP type I receptor in enchondromatosis

  2002cited by this paper
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone

  2002cited by this paper
• D-2-hydroxyglutaric aciduria in association with spondyloenchondromatosis

  2000cited by this paper
• A case of Ollier's disease associated with two intracerebral low-grade gliomas.

  1999cited by this paper
• Diffuse brain stem tumor in an adolescent with multiple enchondromatosis (Ollier's disease)

  1999cited by this paper
• Simultaneous occurrence of a supra- and an infratentorial glioma in a patient with Ollier’s disease: more evidence for non-mesodermal tumor predisposition in multiple enchondromatosis

  1998cited by this paper
• Identical twins with Ollier's disease and intracranial gliomas: case report.

  1994cited by this paper
• Acute lymphoid leukemia associated with Maffucci's syndrome.

  1993cited by this paper
• Multiple enchondromatosis (Ollier's disease) complicated by malignant astrocytoma.

  1991cited by this paper
• Case report 602: Spindle cell hemangioendothelioma (SCH) and enchondromatosis (a form of Maffucci syndrome) in a patient with acute myelocytic leukemia (AML).

  1990cited by this paper
• Maffucci's syndrome with frontal lobe astrocytoma.

  1990cited by this paper
• Ollier's disease and maffucci's syndrome: distinct entities or a continuum

  1988cited by this paper
• A case of Ollier's disease associated with two intracranial gliomas.

  1987cited by this paper
• Characterization of a newly derived human sarcoma cell line (HT‐1080)

  1974cited by this paper
• CARTILAGE TUMOURS.

  1964influential reference
• Pathological Society of Great Britain and Ireland

  1956influential reference

• Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

  2026cites this paper
• Periosteal Chondroma: Ultrasound with Magnetic Resonance Imaging Correlation for Diagnosis of a Bone Surface Tumor

  2026cites this paper
• Malignant transformation of fibrous dysplasia in long bones: a clinicopathological and molecular study of 19 cases

  2026cites this paper
• THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA

  2026cites this paper
• Nanomedicines: An Update of Diagnostic and Therapeutic Applications in Multiple Cancers.

  2026cites this paper
• Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.

  2026cites this paper
• Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs

  2026cites this paper
• Chondromyxoid Fibroma: An Updated Review

  2026cites this paper
• The CFDE Workbench: Integrating Metadata and Processed Data from Common Fund Programs.

  2026cites this paper
• Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1

  2025cites this paper
• Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells

  2025cites this paper
• Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma

  2025cites this paper
• Recent Advances in MXene-Based Screen-Printed Electrochemical Sensors for Point-of-Care Biomarker Detections

  2025cites this paper
• The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling

  2025cites this paper
• Predicting survival outcomes in dedifferentiated chondrosarcoma: a prognostic factor analysis from a National Registry

  2025cites this paper
• Cartilage Tumors.

  2025cites this paper
• Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1).

  2025cites this paper
• Bizarre Parosteal Osteochondromatous Proliferation Revisited

  2025cites this paper
• Clinical insights into circulating free-DNA in patients with bone sarcomas and ewing sarcoma

  2025cites this paper
• IDH Mutations in Chondrosarcoma Correlate with Patient Survival in De-Differentiated but Not Conventional Subtypes

  2025cites this paper
• Application of patient derived xenograft model in personalized drug screening for chondrosarcoma of head and neck: A preclinical study.

  2025cites this paper
• From Inhibitors to PET: SAR-Based Development of [18F]SK60 for mIDH1 Imaging

  2025cites this paper
• Mitochondrial Metabolomics in Cancer: Mass Spectrometry-Based Approaches for Metabolic Rewiring Analysis and Therapeutic Discovery

  2025cites this paper
• Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

  2025cites this paper
• Epigenetic regulation of ferroptosis in gastrointestinal cancers (Review)

  2025cites this paper
• Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches

  2025cites this paper
• IDH-mutant gliomas in children and adolescents - from biology to clinical trials

  2025cites this paper
• Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.

  2025cites this paper
• Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application

  2025cites this paper
• Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.

  2025cites this paper
• Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors.

  2025cites this paper
• Role of Fine-Needle Aspiration Biopsy of Bone Tumors.

  2025cites this paper
• C. elegans Cytoplasmic Isocitrate Dehydrogenase Neomorphic G98N and R133H Mutants Produce the Oncometabolite 2-Hydroxyglutarate

  2025cites this paper
• Pediatric Osteosarcoma and Chondrosarcoma: Recent Advances and Future Directions in Diagnosis and Treatment

  2025cites this paper
• An integrated clinical genomic and transcriptomic subgrouping of central chondrosarcoma.

  2025cites this paper
• Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.

  2025cites this paper
• Impairment of Tricarboxylic Acid Cycle (TCA) Cycle in Alzheimer's Disease: Mechanisms, Implications, and Potential Therapies

  2025cites this paper
• The basic science of musculoskeletal tumours

  2025cites this paper
• Protein Phosphatase 1 Regulatory Subunit 3C integrates cholesterol metabolism and isocitrate dehydrogenase in chondrocytes and neoplasia

  2025cites this paper
• Exploring IDH1 and IDH2 Mutations in Paediatric Medulloblastoma.

  2025cites this paper
• Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma

  2025cites this paper
• Scaffold modification and synthesis routes for targeting mutant IDH 1: a review

  2025cites this paper
• Therapeutic targeting of chromatin alterations in leukemia and solid tumors

  2025cites this paper
• Periosteal Chondroma of Metatarsal Bone in an Elderly Male Patient: A Diagnostic Dilemma

  2025cites this paper
• Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets

  2025cites this paper
• Establishment and characterization of NCC-dCS2-C1: a novel patient-derived cell line of dedifferentiated chondrosarcoma

  2025cites this paper
• Misdiagnosis of chordoma: A case report and a review of the literature

  2025cites this paper
• Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting

  2025cites this paper
• BCOR‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

  2025cites this paper
• IDH mutant high-grade gliomas

  2025cites this paper
• Tracheal Chondrosarcoma: A Case Report and Discussion

  2025cites this paper
• Tumors of the Synovium.

  2025cites this paper
• Case of Enchondroma of Left 4th Metacarpal of Hand Treated with Excision and Bone Grafting with Left 2nd Metatarsal of Foot: A Rare Case Report

  2025cites this paper
• A case of periosteal chondroma in the articular process of mandible

  2025cites this paper
• First Report of NSCLC With IDH1 Mutation: A Case Report.

  2025cites this paper
• Advancing Systemic Therapy in Chondrosarcoma: New Horizons

  2024cites this paper
• Chitosan Nanoparticle-Mediated Delivery of Alstonia venenata R.Br. Root Methanolic Extract: A Promising Strategy for Breast Cancer Therapy in DMBA-Induced Breast Cancer in Sprague Dawley Rats

  2024cites this paper
• Research trends and foci in chondrosarcoma: A bibliometric and network analysis

  2024cites this paper
• Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature

  2024cites this paper
• IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

  2024cites this paper
• Cartilage Forming Tumors of the Skeleton

  2024cites this paper
• IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

  2024cites this paper
• A Rare Entity of the Anterior Chest Cage Rib Chondrosarcoma: A Case Report and Review of Literature.

  2024cites this paper
• Molecular insights and functional analysis of isocitrate dehydrogenase in two gram-negative pathogenic bacteria

  2024cites this paper
• Single cell analysis of Idh mutant growth plates identifies cell populations responsible for longitudinal bone growth and enchondroma formation

  2024cites this paper
• Mesenchymal Chondrosarcoma of the Mandible, a Big Dilemma: Report of a Rare Case in Mesenchymal Chondrosarcoma of the Mandible—Report of a Case With Discussion of Diagnostic and Therapeutic Dilemmas

  2024cites this paper
• Prevalence of SPOP and IDH Gene Mutations in Prostate Cancer in a Jordanian Population

  2024cites this paper
• Ollier Disease, Acute Myeloid Leukemia, and Brain Glioma: IDH as the Common Denominator

  2024cites this paper
• Updates in non-neoplastic orthopaedic pathology: what you don’t know can hurt you!

  2024cites this paper
• Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1)

  2024cites this paper
• Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer.

  2024cites this paper
• Neomorphic IDH Heterodimer Mutants: An Underestimated Point in Cancer Pathogenesis.

  2024cites this paper
• Secondary Chondrosarcoma of the Rib in a Case of Diaphyseal Aclasis: A Rare Case Report

  2024cites this paper
• Global research development of chondrosarcoma from 2003 to 2022: a bibliometric analysis

  2024cites this paper
• A perioperative study of Safusidenib in patients with IDH1-mutated glioma

  2024cites this paper
• Molecular developments in parasellar tumors and potential therapeutic implications.

  2024cites this paper
• Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.

  2024cites this paper
• [Malignant transformation of Ollier disease-related multiple glioma with IDH1 p.R132C mutation].

  2024cites this paper
• The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs)

  2024cites this paper
• Molecular confirmation that fibrocartilaginous dysplasia is a variant of fibrous dysplasia

  2024cites this paper
• Japanese orthopaedic association (JOA) clinical practice guidelines on the management of malignant bone tumors - Secondary publication.

  2024cites this paper
• Targeting DNA Methylation Machinery in Pediatric Solid Tumors

  2024cites this paper
• Atypical Presentation of Periosteal Chondroma of the Talus in a 9-Year-Old Boy: A Case Report

  2024cites this paper
• Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives

  2024cites this paper
• Current advance of nanotechnology in diagnosis and treatment for malignant tumors

  2024cites this paper
• Mitochondrial signaling pathways and their role in cancer drug resistance.

  2024cites this paper
• Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care.

  2024cites this paper
• The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy

  2024cites this paper
• Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors

  2024cites this paper
• Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?

  2024cites this paper
• Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies

  2024cites this paper
• Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia

  2024cites this paper
• Giant skull base periosteal chondroma treated with endonasal endoscopic surgery: illustrative case

  2024cites this paper
• Update of cartilaginous tumours according to the WHO classification 2020.

  2024cites this paper
• A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma

  2024cites this paper
• SMARCB1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma

  2024cites this paper
• Diagnostics of IDH1/2 Mutations in Intracranial Chondroid Tumors: Comparison of Molecular Genetic Methods and Immunohistochemistry

  2024influential citation
• A single-cell atlas of conventional central chondrosarcoma reveals the role of endoplasmic reticulum stress in malignant transformation

  2024cites this paper
• DNA methylation in human diseases

  2024cites this paper
• Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?

  2024cites this paper